Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:FLKS

Flex Pharma (FLKS) Stock Price, News & Analysis

Flex Pharma logo

About Flex Pharma Stock (NASDAQ:FLKS)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$0.81
$0.91
50-Day Range
$0.57
$14.51
52-Week Range
$0.26
$1.49
Volume
116,065 shs
Average Volume
2.03 million shs
Market Capitalization
$15.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Flex Pharma, Inc., a biotechnology company, develops and commercializes products for the treatment of muscle cramps, spasms, and spasticity associated with neurological conditions and exercise-associated muscle cramps in the United States. It operates in two segments, Consumer Operations and Drug Development. The company's lead drug candidate is FLX-787, a single molecule, chemically synthesized, and dual transient receptor potential V1/A1 ion channel activator, which completed an exploratory Phase II clinical trial in Australia for the treatment of patients with multiple sclerosis. It also offers HOTSHOT, a consumer beverage to prevent and treat exercise associated muscle cramps. The company markets and sells its HOTSHOT products online through its direct-to-consumer Website and through third-party Websites, including a retailer that offers international shipping. Flex Pharma, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Remove Ads
Receive FLKS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Flex Pharma and its competitors with MarketBeat's FREE daily newsletter.

FLKS Stock News Headlines

FLEX LNG Ltd. (FLNG) Q2 2024 Earnings Call Transcript
Elon Tax Shock?
Elon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax authorities have bought a powerful new AI supercomputer, worth millions of dollars. It's the most advanced technology offered by AI giant Nvidia. And it's almost certainly going to be used to advance Elon Musk's real agenda with DOGE... the massive, rapid roll out of AI across the entire federal government.
Wayfair Inc. (W) Q2 2024 Earnings Call Transcript
Q2 2024 AGCO Corp Earnings Call
Flex Ltd. (FLEX) Q1 2025 Earnings Call Transcript
Flex Ltd.: Undervalued With Solid Fundamentals
See More Headlines

FLKS Stock Analysis - Frequently Asked Questions

Flex Pharma Inc (NASDAQ:FLKS) announced its quarterly earnings data on Wednesday, May, 1st. The biotechnology company reported ($0.12) EPS for the quarter. The biotechnology company earned $0.11 million during the quarter. Flex Pharma had a negative net margin of 1,208.42% and a negative trailing twelve-month return on equity of 98.04%.

Flex Pharma (FLKS) raised $60 million in an initial public offering (IPO) on Thursday, January 29th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and JMP Securities, Cantor Fitzgerald and Roth Capital Partners were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Flex Pharma investors own include Micron Technology (MU), Ocular Therapeutix (OCUL), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), Celldex Therapeutics (CLDX), Gilead Sciences (GILD) and Histogenics (HSGX).

Company Calendar

Last Earnings
5/01/2019
Today
3/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FLKS
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-21,920,000.00
Net Margins
-1,208.42%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$840,000.00
Price / Cash Flow
N/A
Book Value
$0.51 per share
Price / Book
1.69

Miscellaneous

Free Float
N/A
Market Cap
$15.58 million
Optionable
Not Optionable
Beta
1.65
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:FLKS) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners